Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04, FiscalAI reports.
Acumen Pharmaceuticals Price Performance
Acumen Pharmaceuticals stock opened at $1.98 on Monday. Acumen Pharmaceuticals has a fifty-two week low of $1.50 and a fifty-two week high of $3.60. The stock has a market cap of $143.19 million, a PE ratio of -1.21 and a beta of 0.33. The firm’s 50-day simple moving average is $2.52 and its 200 day simple moving average is $2.46. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.47 and a current ratio of 2.47.
Analysts Set New Price Targets
Several research analysts recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of Acumen Pharmaceuticals in a research report on Wednesday, September 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Friday, October 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Acumen Pharmaceuticals in a research report on Thursday, September 17th. Citigroup raised their price objective on Acumen Pharmaceuticals from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Finally, Wall Street Zen cut Acumen Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Acumen Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $7.00.
Get Our Latest Analysis on ABOS
Acumen Pharmaceuticals Company Profile
Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease and other neurodegenerative disorders. The company’s research centers on amyloid beta oligomers, toxic protein assemblies that Acumen believes contribute to the development and progression of Alzheimer’s disease.
Acumen’s lead product candidate is sabirnetug, also known as ACU193, an investigational humanized monoclonal antibody designed to selectively target soluble amyloid beta oligomers.
Read More
- Five stocks we like better than Acumen Pharmaceuticals
- Amazon’s $350 Price Target Faces a Big Earnings Test
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
